Browsing by Author Bendall, Linda

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 21 to 40 of 54 < previous   next >
Issue DateTitleAuthor(s)Citation
2010Extreme lymphoproliferative disease and fatal autoimmune thrombocytopenia in FasL- and TRAIL-double deficient miceAlexander, Stephen; Bendall, Linda; Stewart, Graeme; Farrell, Geoff C.; Katewa, Arna; Osvath, Sarah R.; Petterson, Ann; Sedger, Lisa; Children's Hospital Westmead: Paediatrics & Child Health; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium InstituteExtreme lymphoproliferative disease and fatal autoimmune thrombocytopenia in FasL- and TRAIL-double deficient mice, Blood, vol.115, 16,pp 3258-3268
2011FTY720 produces caspase-independent cell death of acute lymphoblastic leukemia cellsBendall, Linda; Bradstock, Kenneth; Hewson, John; Wallington-Beddoe, C; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium Institute; Concord Clinical School: Medicine; Western Clinical School: Medicine (Westmead)FTY720 produces caspase-independent cell death of acute lymphoblastic leukemia cells, Autophagy, vol.7, 7, 2011,pp 707-715
2014G-CSF: From granulopoietic stimulant to bone marrow stem cell mobilizing agentBendall, Linda; Bradstock, Kenneth; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium InstituteG-CSF: From granulopoietic stimulant to bone marrow stem cell mobilizing agent, Cytokine & Growth Factor Reviews, vol.25, 4, 2014,pp 355-367
2005Growth requirements and immunophenotype of acute lymphoblastic leukemia progenitorsBendall, Linda; Bradstock, Kenneth; Campana, D; Iwamoto, D; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium InstituteGrowth requirements and immunophenotype of acute lymphoblastic leukemia progenitors, Blood, vol.105,(10),2005,pp 4150-N/A
2012Hematopoietic stem cell mobilizing agents G-CSF, cyclophosphamide or AMD3100 have distinct mechanisms of action on bone marrow HSC niches and bone formationBendall, Linda; Cisterne, Adam; Barbier, Valerie; Forristal, C E; Jacobsen, R; Levesque, Jean-Pierre; Nowlan, Bianca; Pettit, Allison; Raggatt, Liza Jane; Sims, Natalie A; Winkler, Ingrid; Western Clinical School: Westmead Institute for Medical Res; Western Clinical School: Medicine (Westmead)Hematopoietic stem cell mobilizing agents G-CSF, cyclophosphamide or AMD3100 have distinct mechanisms of action on bone marrow HSC niches and bone formation, Leukemia, vol.26, 7, 2012,pp 1594-1601
2007Interaction of interleukin-7 and interleukin-3 with the CXCL12-induced proliferation of B-cell progenitor acute lymphoblastic leukemiaBaraz, Rana; Bendall, Linda; Bradstock, Kenneth; Gaundar, Shivashni; Juarez, Julius; Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead)Interaction of interleukin-7 and interleukin-3 with the CXCL12-induced proliferation of B-cell progenitor acute lymphoblastic leukemia, Haematologica: the hematology journal, vol.92,(4),2007,pp 450-459
2011The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemiaBendall, Linda; Bradstock, Kenneth; Cisterne, Adam; Saunders, Philip; Weiss, Jocelyn; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Millennium InstituteThe mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia, Haematologica: the hematology journal, vol.96, 1, 2011,pp 69-77
2011Mobilisation strategies for normal and malignant cells.Bendall, Linda; Gottlieb, David; Rasko, John; Antonenas, Vicki; et al, various; Herbert, Kirsten; Hiwase, Devendra; Larsen, Stephen; Levesque, Jean-Pierre; Mills, Anthony; Rice, Allison; To, L; Winkler, Ingrid; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium Institute; Central Clinical School: Centenary InstituteMobilisation strategies for normal and malignant cells., Pathology, vol.43, 6, 2011,pp 547-565
2014mTOR inhibition by everolimus in childhood acute lymphoblastic leukemia induces caspase-independent cell deathBaraz, Rana; Basnett, Jordan; Bendall, Linda; Bradstock, Kenneth; Cisterne, Adam; Hewson, John; Saunders, Philip; Thien, Marilyn; Weiss, Jocelyn; Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead); Concord Clinical School: Medicine; Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Millennium InstitutemTOR inhibition by everolimus in childhood acute lymphoblastic leukemia induces caspase-independent cell death, PloS One, vol.9, 7, 2014,pp 1-10
2005New therapies targeting chemokine receptors: Can changing the way cells traffic be used to treat human disease?Bendall, Linda; Bradstock, Kenneth; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium InstituteNew therapies targeting chemokine receptors: Can changing the way cells traffic be used to treat human disease?, Current Topics in Membranes, vol.55,(N/A),2005,pp 331-365
2003A novel CD44 antibody identifies an epitope that is aberrantly expressed on acute lymphoblastic leukaemia cellsBendall, Linda; Bradstock, Kenneth; Gottlieb, David; James, Alexander; Simmons, Paul J.; Zannettino, Andrew C.W.; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium Institute; MedicineA novel CD44 antibody identifies an epitope that is aberrantly expressed on acute lymphoblastic leukaemia cells, Immunology and Cell Biology, vol.81,(4),2003,pp 311-319
2003Novel mesenchymal and haematopoietic cell isoforms of the SHP-2 docking receptor, PZR: identification, molecular cloning and effects on cell migrationBendall, Linda; Bradstock, Kenneth; Henniker, A; Harrison, Kate L.; Jackson, Denise E.; Niutta, Silvana; Roubelakis, Maria; Simmons, Paul J.; Watt, Suzanne M.; Welldon, Katie J.; Zannettino, Andrew C.W.; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead)Novel mesenchymal and haematopoietic cell isoforms of the SHP-2 docking receptor, PZR: identification, molecular cloning and effects on cell migration, Biochemical Journal, vol.370,(2),2003,pp 537-549
2013Oncogenic properties of sphingosine kinases in haematological malignanciesBendall, Linda; Bradstock, Kenneth; Wallington-Beddoe, Craig; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead)Oncogenic properties of sphingosine kinases in haematological malignancies, British Journal of Haematology, vol.161, 5, 2013,pp 623-638
2005Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cellsBendall, Linda; Bertoncello, Ivan; Denhardt, David T.; Haylock, David N.; Johnston, Hayley M.; Nilsson, Susan K.; Simmons, Paul J.; Webb, Ryan J.; Whitty, Genevieve A.; Williams, Brenda; Western Clinical School: Westmead Millennium InstituteOsteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells, Blood 2005, vol.106,(4),2005,pp 1232-1239
2009p38MAPK inhibitors attenuate cytokine production by bone marrow stromal cells and reduce stroma-mediated proliferation of acute lymphoblastic leukemia cellsBendall, Linda; Gaundar (nee Deo), Shivashni; Bradstock, Kenneth F.; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium Institutep38MAPK inhibitors attenuate cytokine production by bone marrow stromal cells and reduce stroma-mediated proliferation of acute lymphoblastic leukemia cells, Cell Cycle, vol.8, 18,pp 2977-2985
2012Para-NO-aspirin inhibits NF-kB and induces apoptosis in B-cell progenitor acute lymphoblastic leukemiaBaraz, Rana; Bendall, Linda; Bradstock, Kenneth; Cisterne, Adam; Khan, Naveed; Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Millennium InstitutePara-NO-aspirin inhibits NF-kB and induces apoptosis in B-cell progenitor acute lymphoblastic leukemia, Experimental Hematology, vol.40, 3, 2012,pp 207-215.e1
2015A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic LeukemiaBasnett, Jordan; Bendall, Linda; Boumber, Yanis; Cortes, Jorge E.; Culotta, Kirk; Daver, Naval; et al, Various; Kantarjian, Hagop; Kawedia, Jitesh; Ravandi, Farhad; Rytting, Michael E; Zeng, Zhihong; Western Clinical School: Westmead Institute for Medical Res; Western Clinical School: Westmead Institute for Medical ResA Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia, Clinical Cancer Research, vol.21, 12, 2015,pp 2704-2714
2013Plerixafor (AMD3100) induces prolonged mobilization of acute lymphoblastic leukemia cells and increases the proportion of cycling cells in the blood in miceBasnett, Jordan; Bendall, Linda; Bradstock, Kenneth; Dela Pena, Aileen; Juarez, Julius; Welschinger, Robert; Liedtke, Florian; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead); Infectious DiseasesPlerixafor (AMD3100) induces prolonged mobilization of acute lymphoblastic leukemia cells and increases the proportion of cycling cells in the blood in mice, Experimental Hematology, vol.41, 3, 2013,pp 293-302.e1
2010The Potential and Limitations of p38MAPK as a Drug Target for the Treatment of Hematological MalignanciesBendall, Linda; Deo, Shivashni Swasthika; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium InstituteThe Potential and Limitations of p38MAPK as a Drug Target for the Treatment of Hematological Malignancies, Current Drug Targets, vol.11, 7, 2010,pp 823-833
2009Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemiaBaraz, Rana; Bendall, Linda; Bradstock, Kenneth; Cisterne, Adam; Crazzolara, Roman; Hewson, John; Thien, Marilyn; Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead); Nepean Clinical School: Medicine; Concord Clinical School: Medicine; Western Clinical School: Medicine (Westmead)Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia, Blood, vol.113, 14, 2009,pp 3297-3306